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Abstract 
Purpose: To evaluate the potential of PEGylated 64Cu-liposomes in clinical diagnostic PET imaging and 
PEGylated 177Lu-liposomes in internal tumor radiotherapy through in vivo characterization and dosimetric 
analysis in a human xenograft mouse model. Methods: 5 mol% and 10 mol% PEG liposomes were characterized 
with respect to size, charge, and 64Cu- and 177Lu-loading efficiency. The tumor-imaging potential of 64Cu-loaded 
liposomes was evaluated using PET-imaging in terms of in vivo biodistribution, tumor accumulation and tumor-
to-muscle (T/M) ratios. The potential of PEGylated liposomes for diagnostic and therapeutic applications were 
further evaluated through dosimetry analysis using OLINDA/EXM software. The 64Cu-liposomes were used as 
biological surrogates to estimate the organ and tumor kinetics of 177Lu-liposomes. Results: High remote loading 
efficiency (>95%) was obtained for both 64Cu and 177Lu radionuclides with PEGylated liposomes and essentially 
no leakage of the encapsulated radionuclide upon storage and after serum incubation for 24 h at 37°C was 
observed. The 10 mol% PEG liposomes showed highest tumor accumulation (6.2 ± 0.2 %ID/g) compared to 5 
mol% PEG liposomes, which was evaluated by PET imaging. The dosimetry analysis of the 64Cu-liposomes 
estimated an acceptable total effective dose of 3.3·10-2 mSv/MBq for diagnostic imaging in patients. A high-
absorbed tumor dose (114 mGy/MBq) was estimated of the potential radiotherapeutic 177Lu-liposomes. 
Conclusion: The overall preclinical profile of PEGylated 64Cu-liposomes showed high potential as a new PET 
theranostic tracer for imaging in humans. Dosimetry results predicted that a starting administration activity of 
200 MBq of 64Cu-liposomes should be acceptable in patients. Work is in progress to validate the utility of 
PEGylated 64Cu-liposomes in a clinical research programme. The high-absorbed tumor dose (114 mGy/MBq) 
estimated for 177Lu-liposomes and the preliminary dosimetric studies justify further therapeutic and dosimetry 
investigations of 177Lu-liposomes in animals before potential testing in man. 
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Introduction  
The most commonly used PET tracer 2-[18F]fluoro-
2-deoxy-D-glucose (FDG) has become an important 
tool in diagnostic and prognostic evaluation of 
cancer patients as well as for monitoring patient 
response to therapy [1-5]. FDG is mainly suitable 
for diagnosing tumors with high proliferative 
activity [1,6] and has limited diagnostic value for 
several cancer forms such as highly differentiated 
neuroendocrine (NE) [7,8] and prostatic tumors 
[9,10]. PET isotopes such as 18F, 15O, 13N and 11C 
have relative short half-lives where only early 
imaging time-points are possible, leaving biological 
processes with duration of several hours or days 
impossible to explore [11]. Tumor imaging using 
the longer lived PET isotope 64Cu, with favorable 
decay characteristics (12.7 h), permit studies for as 
long as 48 h after injection [12,13]. Isotopes 
emitting beta-radiation for short-range local 
radiation therapy can be used for treatment of 
tumors if the radioisotopes can be targeted 
specifically to the diseased tissue. NE tumors are 
known to express specific tumor markers, and 
approximately 90% of NE tumors have somatostatin 
receptors over-expressed on tumor cell surfaces 
[14]. Accordingly, these patients are well suited for 
peptide receptor radionuclide therapy (PRRT), 
which has been used for approximately 10 years 
based on either 90Y-DOTATOC or 177Lu-
DOTATATE [15-17]. The dose-limiting organs for 
PRRT are the kidney and bladder due to renal 
excretion of the peptide-based tracer, and tracers 
limiting this absorbed dose to normal organs are 
warranted. Another targeting approach is the use of 
surface modified liposomes with polymers, such as 
polyethylene glycol (PEG), that strongly reduce 
reticuloendothelial system (RES) uptake, thereby 
prolonging liposome circulation half-life, which 
enhances tumor accumulation by the enhanced 
permeation and retention (EPR) effect [18].  
Several studies on PEGylated liposomes have 
been performed [18-22] and the optimum level of 
PEGylation has been extensively discussed [23]. 
Moreover, characteristics such as tumor size, cancer 
type and degree of tumor vascularity have a high 
impact on the degree of tumor extravasation of 
PEGylated liposomes. A previous study has 
observed a trend to higher 111In-liposome uptake in 
smaller and more vascular tumors using SPECT 
imaging [24].  
Using our recently reported remote loading 
method to entrap 64Cu in liposomes [25] we here 
report a study to evaluate the diagnostic 
performance of 64Cu loaded PEGylated liposomes in 
a human xenograft animal model using PET 
imaging. The study is the first to use PET imaging 
to investigate the optimal level of PEGylation in 
liposomes and how this influences the 
biodistribution and tumor accumulation in tumors of 
different sizes. The diagnostic potential and safety 
of 64Cu-liposomes as a new PET tracer for clinical 
use are evaluated through a dosimetry study. In 
addition, we show the new possibilities with the 
remote loading method by investigating the 
therapeutic radionuclide, 177Lu, into PEGylated 
liposomes. A dosimetric analysis is performed to 
evaluate the potential and safety of the liposomes as 
carriers of 177Lu radionuclides in internal tumor 
radiotherapy based on the 64Cu-liposome 
biodistribution data.  
 
Materials and Methods  
Preparation of PEGylated liposomes  
PEGylated liposomes consisting of 1,2-distearoyl-
sn-glycero-3-phosphocholine (DSPC), cholesterol 
(CHOL) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (polyethylene 
glycol)-2000] (DSPE-PEG2000) in the molar ratio 
55:40:5 (5 mol% PEG liposomes) or 50:40:10 (10 
mol% PEG liposomes) were prepared as described 
previously [25]. The size and zeta-potential of the 
liposomes were measured on a ZetaPALS 
instrument (Brookhaven, Holtsville, NY) and the 
lipid concentrations were determined by ICP-OES 
(Vista AX, Varian, Palo Alto, CA). The chelating 
agent, 1,4,7,10-tetra-azacyclododecane-1,4,7,10-
tetraacetic acid (DOTA, 10 mM) was trapped within 
the liposomes during the thin-film hydration and 
DOTA outside the liposomes was removed by size 
exclusion chromatography (SEC) (Sephadex G-25) 
eluted with HEPES buffer (10 mM, pH 7.4, 150 
mM NaCl). All lipids were purchased for Avanti 
Polar Lipids, DOTA was purchased from 
Macrocyclics, and all other chemicals from Sigma 
Aldrich.  
 
Cryo-TEM imaging 
Electron microscopy studies were performed using a 
Philips CM120 BioTWIN transmission electron 
microscope with a cryo-holder and a cryo-transfer 
stage. The sample preparation procedure was done 
as described previously [26]. The sample was 
prepared with a final lipid concentration of 10 mM, 
and was equilibrated at ambient temperature for 24 
h before vitrification. 
 
64Cu production 
Copper-64 was produced on a PETtrace cyclotron 
(GE Healthcare) equipped with a beamline. The 
production of 64Cu was carried out via the 
64Ni(p,n)64Cu nuclear reaction as described 
previously [25].  
 
64Cu loading into PEGylated liposomes 
The remote loading of 64Cu into PEGylated 
liposomes has been reported recently [25]. Briefly, 
10 µL 2-hydroxyquinoline (2HQ) (0.314 mM) in 
HEPES buffer (10 mM, pH 7.4, 150 mM NaCl) was 
added to a dry vial containing radioactive 64CuCl2 (∼ 
400 MBq). 500 µL DOTA-containing PEGylated 
liposomes were added followed by incubation (60 
min). The 64Cu-liposomes were purified using a 
Sephadex G-25 column, eluted with HEPES buffer 
(10 mM, pH 7.4, 150 mM NaCl).  
 
177Lu loading into PEGylated liposomes 
177Lu-liposomes were prepared and analyzed 
following the same procedure as the 64Cu-liposomes 
described above. The radioactive 177LuCl3 was 
purchased from Pelkin Elmer. 
 
Liposomal in vitro stability   
Purified 64Cu-liposome or 177Lu-liposome solutions 
were tested for radionuclide retention stability by 
incubating for 24 h at 37°C or 20°C. The 
radionuclide retention stability was assayed by 
measuring the amount of un-encapsulated 
radionuclides and encapsulated radionuclides by 
SEC. Additionally stability in human serum of the 
64Cu-liposome and 177Lu-liposome solutions was 
tested by mixing human serum and liposome 
solutions (1:1) at 37°C for 24 h followed by SEC. 
 
Animal models 
Human neuroendocrine tumor cells (NCI-H727) (5 
x 106 cells) were inoculated in the left and right 
flank of female NMRI (Naval Medical Research 
Institute) nude mice (n = 30) in a 1:1 mixture of 
suspended cells and Matrixgel™ (BD Biosciences, 
San Jose, CA, USA) and allowed to grow 3 weeks 
(small tumors : < 0.5 g; n = 26) or 4 weeks (large 
tumors: > 0.5 g < 1.2 g; n = 14). All nude mice were 
purchased from Taconic (Borup, Denmark), and all 
experimental procedures were conducted with the 
guidelines set forth by the Danish Ministry of 
Justice. 
 
Acquisition protocol 
Purified PEGylated 64Cu-liposome suspensions 
were administered intravenously (i.v.) for 
biodistribution imaging and quantification. All 
animals were anesthetized with sevofluran and 
catheterized to ensure proper tail vein injection. The 
average administered lipid dose levels of both 
liposome formulations (5 mol% PEG and 10 mol% 
PEG liposomes) were 10 mg/kg (7.8 ± 1.4 
MBq/animal) (n = 30). After the last PET scan at 24 
or 48 h time-point the mice were sacrificed, and 
tissues and organs of interest - including the blood, 
heart, liver, spleen, kidney, lung, small intestine, 
pancreas, tumors and quadriceps muscle were 
harvested, and the level of activity in each tissue 
was measured using a gamma counter. Positron 
emission tomography (PET) data were acquired on 
a MicroPET® Focus 120 (Siemens Medical 
Solutions, Malvern, PA, USA). The voxel size was 
0.866 x 0.866 x 0.796 mm3 and in the centre field of 
view the resolution was 1.4 mm. To ensure proper 
signal-to-noise ratios PET scans were acquired over 
20 min for the first three scans (1 h, 8 h and 24 h) 
and 40 min for the late scan (48 h). Data were 
reconstructed with the maximum a posterior (MAP) 
reconstruction algorithm. For anatomical 
localization of activity, computer tomography (CT) 
images were acquired with a MicroCAT® II system 
(Siemens Medical solutions, Malvern, PA, USA) 
with X-ray tube settings of 62 kVp and 500 µA. CT 
images were acquired in a 7-min scan with 360 
rotation steps, a 390 ms exposure time and voxel 
size of 0.095 x 0.095 x 0.095 mm3. 
 
Data analysis 
After data reconstruction PET- and CT images were 
fused using the Inveon Software (Siemens). The 
emission scans were corrected for random counts 
and dead time. The PET- and CT images were used 
to identify regions of tracer uptake (source organs) 
and generate regions of interest (ROIs). Those 
organs that either were identifiable from the CT 
image or had tracer uptake significantly above 
background were used as source organs. The organs 
used were spleen, liver, kidney, left ventricle and 
tumor. In organs where activity could not be 
accurately measured on PET images, data from the 
gamma counter were used. Those organs were the 
lung, intestine and pancreas due to poor visibility on 
CT. The blood concentration was measured from 
the tracer concentration within the left ventricle in 
the heart [25]. Activity in muscle was quantified by 
drawing ROIs on the quadriceps muscle, which was 
well distanced, from the tumor in the flank. The 
percentage of the injected liposomal dose in blood 
(%IDblood), the terminal half-life of the liposomal 
blood clearance (𝑇½!)  and the mono-exponential 
function used for description of the injected dose in 
blood are defined and calculated according to 
Equations 1-3 in Appendix B. The percentage of 
injected dose per gram (%ID/g) in the different 
organs and tumors and the standardized uptake 
value (SUV) are defined and calculated according to 
Equations 4-5 in Appendix B. The residence time 
(𝑇!) from each source organ is used as input in the 
software OLINDA/EXM [27] and is calculated 
according to Equation 6 in Appendix B. Human 
absorbed radiation doses were estimated using the 
standard male phantom, and mean absorbed tumor 
doses were estimated using the unit density sphere 
module. The residence time assigned to the 
remainder-of-body comprises the full body dose 
(injected dose) subtracting the source organ doses. 
This estimate is thus an upper limit since urine 
excretion was not accounted for. 
 
Statistics 
In vivo results are shown as means ± standard error 
of the mean (SEM). The values were analyzed with 
a one-tail unpaired t test for significant differences 
(experiments comparing two groups of animals). P 
values of less than 0.05 were considered significant.  
Results  
Characterization of PEGylated liposomes   
To evaluate the influence of the degree of 
PEGylation on tumor accumulation and diagnostic 
and therapeutic potential, two PEGylated liposome 
formulations with 5 mol% and 10 mol% DSPE-
PEG2000 were prepared. The mean diameter of 
liposomes with 5 mol% PEG was 100 nm (PDI = 
0.025) and 116 nm (PDI = 0.038) for liposomes 
with 10 mol% PEG. The zeta potential was -16.0 ± 
0.4 mV and -17 ± 2 mV, and the phospholipid 
concentration was 3.4 ± 0.1 mM and 3.3 ± 0.1 mM 
for 5 mol% PEG and 10 mol% PEG liposomes, 
respectively. Fig. 1 shows a cryo-TEM (cryo-
transmission electron microscopy) image of 
PEGylated liposomes containing 10 mol% DSPE-
PEG2000, where the dominating sample morphology 
is unilamellar spherical liposomes with sizes in the 
range 60-120 nm. 64Cu2+ was remotely loaded into 
the PEGylated liposomes using 2HQ and DOTA. 
The 64Cu loading efficiency of the two liposome 
formulations was comparable (95 ± 0.5% for 5 
mol% PEG liposomes and 96 ± 2% for 10 mol% 
PEG liposomes) (Fig. 2A), when liposomes were 
incubated with 64Cu-2HQ. When incubating the 
64Cu-liposomes in human serum at 37°C for 24 h, 
the fraction of radionuclide retained in both 
PEGylated liposome formulations was >99% (Fig. 
2A insert). 
 
 
Fig. 1 Cryo-TEM (cryo-transmission electron microscopy) 
image of 10 mol% PEG liposomes consisting of 
DSPC/CHOL/DSPE-PEG2000 (50:40:10) with 10 mM 
DOTA encapsulated. 
 
 
Fig. 2 Size exclusion chromatography (SEC) separation 
profile of 64Cu-liposomes and free 64Cu radionuclide using a 
Sephadex G-25 column. (A) Preformed liposomes 
consisting of DSPC/CHOL/DSPE-PEG2000 (50:40:10) with 
encapsulated DOTA (10 mM) loaded with 64Cu using 2HQ 
showed high loading efficiency (96% ± 2%, n = 10). Insert: 
A stability test with no leakage of 64Cu from the 64Cu-
liposomes after incubation in human serum for 24 h at 37°C. 
(B) Preformed liposomes consisting of DSPC/CHOL/DSPE-
PEG2000 (50:40:10) with encapsulated DOTA (10 mM) and 
loaded with 177Lu using 2HQ with high loading efficiency 
(96.7% ± 0.3%, n = 4). Insert: A stability test of 177Lu 
loaded liposomes with no leakage (<1%) after incubation in 
human serum for 24 h at 37°C. 
Loading efficiency and retention stability of 
PEGylated 177Lu-liposomes 
The loading method was also utilized to load 177Lu3+ 
into DOTA-containing liposomes. The 177Lu 
loading efficiency was similar (96.7% ± 0.3%, Fig. 
2B) to the 64Cu loading into 10 mol% PEG 
liposomes. The 177Lu PEGylated liposomes were 
stable with minimal leakage (<1%) of the 
encapsulated radionuclide upon storage and after 
incubation for 24 h at 37°C in serum (Fig. 2B 
insert).   
Impact of PEGylation on liposomes biodistribution 
and tumor accumulation 
The in vivo performance of PEGylated liposomes 
was evaluated in the human neuroendocrine 
carcinoma H727-bearing mouse model by PET 
imaging analysis. The blood clearance profiles (Fig. 
3) were fitted by a mono-exponential curve and data 
was treated as described in Appendix B. For 5 
mol% PEG liposomes, 40 ± 2% of the injected dose 
was cleared from the blood within the first hour 
while the remaining circulating part was cleared 
with a half-life of 𝑇½! = 10.3 ± 0.3 h. For 10 mol% 
PEG liposomes a significant lower fraction (30 ± 
2%) of the injected dose was initially cleared from 
the blood compared to the 5 mol% PEG liposomes 
(P < 0.001). However, the long circulating parts 
were cleared at comparable rates for both 
formulations (10 mol% PEG liposomes, 𝑇½! = 10.7 
± 1.0 h).   
 
 
Fig. 3 Blood concentration of 5 mol% PEG 64Cu-liposomes 
(n = 10) and 10 mol% PEG 64Cu-liposomes (n = 10) in 
tumor-bearing mice expressed as percent injected dose 
(%ID) as function of time. The blood concentration was 
estimated from a ROI drawn around the left ventricle on 
axial PET/CT fusion images. All values are means ± SEM. 
 
The uptake in the spleen was relatively high after 1 
h as expected and continued to increase throughout 
the first 24 h where a peak value for both liposome 
formulations was reached (Table 1). There was no 
significant difference in the spleen uptake between 
the two formulations. In contrast, a significant 
higher uptake of the 10 mol% PEG liposomes in the 
liver was observed 1 h (P = 0.006) and 8 h (P = 
0.004) (Table 1) compared to 5 mol% PEG 
liposomes. However, at 24 h and 48 h the uptake in 
the liver was comparable for both liposome 
formulations. There was no significant difference in 
kidney uptake between the two liposome 
formulations, and the activity localized in the lungs, 
pancreas and intestine was low for both liposome 
formulations (Table 1). The tumor accumulation of 
10 mol% PEG liposomes was significantly higher 
compared to 5 mol% PEG liposomes at the 24 h (P 
= 0.009) and 48 h (P = 0.017) time-points (Table 1). 
The T/M ratio of both liposomal formulations was 
high at all time-points with a peak value (24 h post-
injection) of 11.3 ± 1.3 for 5 mol% PEG liposomes 
and 8.9 ± 0.9 for 10 mol% PEG liposomes, a 
difference that is borderline significant (P = 0.062). 
Due to higher tumor accumulation of the 10 mol% 
PEG liposomes, the therapeutic potential of this 
formulation was further evaluated as a function of 
tumor size.  
Impact of tumor size on tumor accumulation 
The tumor accumulation of 10 mol% PEG 
liposomes were evaluated as a function of tumor 
size (small tumors (< 0.5 gram; n = 26), large 
tumors (> 0.5 < 1.2 gram; n = 14) and as a function 
of time (Fig. 4). A significantly higher liposomal 
uptake (%ID/g) was observed in small tumors at the 
24 h (P < 0.001) and 48 h (P < 0.001) time-points 
compared to large tumors (Fig. 4A). Additionally, a 
significant higher T/M ratio was observed within 
small tumors at 24 h (10.5 ± 0.7; P = 0.02) and at 48 
h (12.4 ± 1.0; P = 0.003) compared to large tumors 
(7.8 ± 1.0 and 8.2 ± 0.6 at 24 h and 48 h 
respectively) (Fig. 4B). The tracer accumulation of 
10 mol% PEG liposomes in small tumors is 
depicted in Fig. 5. Small tumors were visualized 
with radioactive hot spots distributed within the 
whole tumor area, whereas only the rim of larger 
tumors had high radioactivity (data not shown), as 
also visualized in a previous study [25]. 

	Table 1 Biodistribution and tumor accumulation of H727 Tumor-Bearing Mice after Intravenous Administration of 5 mol% PEG 
and 10 mol% PEG liposomes 
                 Time after intravenous administration (h) 
 1 8 24 48 
Organ 5 mol% 10 mol% 5 mol% 10 mol% 5 mol% 10 mol% 5 mol% 10 mol% 
Spleen 14.9 ± 0.6 14.6 ± 0.7 17.5 ± 1.0 16.5 ± 0.8 19.6 ± 1.0 16.9 ± 0.7 15.5 ± 0.7 16.2 ± 1.0 
Liver 7.5 ± 0.4 9.2 ± 0.5* 10.2 ± 0.6 13.8 ± 0.4* 11.5 ± 0.5 11.7 ± 0.4 9.6 ± 0.5 11.4 ± 0.7 
Lungs# NA NA NA NA 2.4 ± 0.3 3.0 ± 0.8 1.9 ± 0.1 1.7 ± 0.1 
Intestine# NA NA NA NA 6.4 ± 0.6 5.9 ± 0.9 5.0 ± 0.4 6.3 ± 0.5 
Pancreas# NA NA NA NA 1.3 ± 0.2 1.3 ± 0.5 0.9 ± 0.1 1.4 ± 0.3 
Kidneys 6.9 ± 0.4 7.9 ± 0.6 5.8 ± 0.3 6.4 ± 0.8 4.8 ± 0.4 5.3 ± 0.3 4.3 ± 0.4 4.9 ± 0.4 
Tumor 1.6 ± 0.1 1.9 ± 0.1 2.3 ± 0.2 3.0 ± 0.2 4.4 ± 0.4 5.9 ± 0.2* 4.9 ± 0.5 6.2 ± 0.2* 
Muscle 1.1 ± 0.2 1.2 ± 0.1 0.6 ± 0.1 0.8 ± 0.1 0.5 ± 0.1 0.8 ± 0.1 0.6 ± 0.1 0.9 ± 0.2 
T/M 1.6 ± 0.2 1.7 ± 0.1 4.2 ± 0.4 3.2 ± 0.25 11.3 ± 1.2 8.9 ± 0.9 9.9 ± 2.3 8.6 ± 1.4 
SUV 0.41 ± 0.04 0.5 ± 0.1 0.6 ± 0.1 0.8 ± 0.2 1.1 ± 0.2 1.6 ± 0.3* 1.3 ± 0.2 1.7 ± 0.2* 
Values are represented as %ID/g, mean ± SEM (n = 10 at 1, 8 and 24 h and n = 5 at 48 h)  
*P < 0.05 versus 5 mol% PEG liposomes; # tissue measurements from gamma counter; NA: not available; T/M: Tumor-to-
muscle; SUV: standardized uptake value 
 
 
Table 2 Average Organ Residence Times, TR, (h) 
 10 mol% PEG liposomes 5 mol% PEG liposomes 
Source organ 64Cu-liposomes 177Lu-liposomes 64Cu-liposomes 177Lu-liposomes 
Kidney 0.2 0.8 0.2 (0.3) 0.8 (2.1) 
Liver 1.5 8.9 1.3 (2.5) 7.7 (21.7) 
Spleen 0.4 2.1 0.4 (0.8) 2.0 (8.4) 
Lung NA NA NA (1.0) NA (6.5) 
Heart 0.5 0.8 0.4 (NA) 0.7 (NA) 
Tumor 0.2 2.7 0.1 (NA) 2.3 (NA) 
REM 16.8 209.9 17.0 (15.6) 210.6 (192.3) 
Values are averaged over all 10 mice in each groups (10 mol% and 5 mol% PEG liposomes) 
( ): residence times calculated based on PEGylated liposomal (5.3 mol% DSPE-PEG2000) biodistribution data from a clinical 
study and is an average of 17 patients [28]; NA: not available; REM: Remainder-of-body 
 
Absorbed dose  
The distribution data of 5 mol% and 10 mol% PEG 
liposomes were used for estimating absorbed 
radiation doses of 64Cu-liposomes and 177Lu-
liposomes for i.v. injection. For comparison the 
liposomal biodistribution data from a clinical study 
[28] was used for estimating the absorbed radiation 
doses by including the physical decay of 64Cu or 
177Lu in determining residence times (Table 2). For  
 
 
 
both 5 mol% and 10 mol% PEG 64Cu-liposomes the 
total effective dose was less than 3.3·10-2 
mSv/MBq, and the organs receiving the highest 
doses were: spleen, liver, stomach wall, lower large 
intestine wall, red marrow and lungs (Table 3 in 
Appendix A), and only limited radiation doses were 
absorbed in the kidney and bladder for both 
formulations. 
 
  
 
Fig. 4 Tumor accumulation of PEGylated liposomes (10 
mol% PEG) in small tumors (< 0.5 gram; n = 26) and in 
large tumors (> 0.5 < 1.2 gram; n = 14). The tumor 
accumulation is expressed as %ID per gram (A) and T/M 
ratio (B). The values represent the mean ± SEM. 
Differences considered to be statistically significant are 
indicated:  * = P < 0.05 and ** = P < 0.01. 
 
An administration of 200 MBq 64Cu-liposomes 
yields a total effective dose of 6.6 mSv and 6.5 mSv 
for the 10 mol% PEG and 5 mol% PEG 64Cu-
liposomes, respectively. A dose of 9.2 mSv is 
obtained (200 MBq administration) when 
calculation are based on liposomal biodistribution 
data from a clinical study [28]. A total effective 
dose less than 2.8·10-1 mSv/MBq for both 
PEGylated 177Lu formulations were estimated 
(Table 4 in Appendix A), where the organs 
receiving the highest dose were: spleen, liver, 
stomach wall, lower large intestine wall, red 
marrow and lungs for both formulations. The longer 
circulating 10 mol% PEG liposomes deposit a 
higher absorbed dose to the tumor (114 mGy/MBq 
for a 2-g tumor and 11.5 mGy/MBq for a 20-g 
tumor), compared to 5 mol% PEG 177Lu-liposomes 
(96.9 mGy/MBq for a 2-g tumor and 9.8 mGy/MBq 
for a 20-g tumor) (Table 4 in Appendix A). 
 
Discussion  
In this study we have evaluated the diagnostic 
potential of PEGylated 64Cu-liposomes in a human 
neuroendocrine carcinoma H727-bearing mouse 
model using PET imaging, where high T/M ratios 
for optimal tumor visualization were found for both 
5 mol% and 10 mol% PEGylated 64Cu-liposomes. 
The loading method used within this study [25] 
entraps 64Cu radionuclides in PEGylated liposomes 
at high concentrations and provides high in vivo 
stability effective for PET imaging. Imaging agents 
based on radiolabeled peptides and substrates are of 
considerable value in nuclear oncology as 
diagnostic tools e.g. for NE tumors, but exhibit 
significantly lower in vivo stability and circulation 
properties compared to the reported 64Cu-liposomes. 
The obtained results within this study look 
promising when %ID/g, SUV and T/M ratios are 
compared with results from radiolabeled peptides 
[11,12]. Imaging agents, such as radiolabeled 
peptides and 18F-FDG, are cleared relatively fast 
from the blood stream through renal clearance 
resulting in a high degree of radioactivity in the 
kidney and bladder. During the imaging period this 
high degree of radioactivity in the kidney and 
bladder makes diagnosing prostate cancer a 
challenge. The size and circulation properties of 
PEGylated liposomes minimize kidney and bladder 
accumulation. In addition the enhanced in vivo 
stability, the high tumor accumulation and reduced 
non-specific binding are all important features 
making the PEGylated 64Cu-liposomes promising as 
diagnostic PET tracer for a variety of cancer types.  
From a drug delivery point of view, the 
optimal level of PEGylation on different liposome 
formulations has been extensively discussed [23]. In 
a study by Chow et al. radiolabeled liposomes 
(111In-liposomes) were tested in animals, where 
effective long-term circulation in the blood and 
maximum tumor uptake was achieved with 6 mol% 
PEGylated 100 nm liposomes [22].  
 
	 
Fig. 5 PET/CT images of tumor accumulation of 5 mol% PEG and 10 mol% PEG 64Cu-liposomes in small tumors at 1, 8, 
24 and 48 h after tracer administration. Left: Coronal whole body PET image. Top right: Axial PET/CT-fusion image of 
tumors. The tumors on right and left flank are marked with arrows. Bottom: Sagital whole body PET/CT-fusion image. The 
head of the mice are not included in the whole body images. 
The measured half-life (𝑇½!) reported in the present 
study was less affected by the PEG level, while the 
initial clearance of the 5 mol% PEG liposomes was 
significantly higher compared to 10 mol% PEG 
liposomes. Thus a higher fraction of 10 mol% PEG 
liposomes is expected to be in the circulation. 
Additionally, we found that inclusion of 10 mol% 
DSPE-PEG2000 in the liposomal membrane 
increased the amount of liposomes found in the 
tumors when compared to 5 mol% DSPE-PEG2000 
liposomes. This observation is in accordance with 
the generally accepted hypothesis that a longer 
blood circulation half-life results in repeated 
passages through the tumor site of high 
concentrations of liposomes, and thereby a greater 
efficiency of extravasation [23,29]. Furthermore, we 
observed a trend to higher liposome uptake in 
smaller tumors per gram tissue as also reported in a 
previous study [24]. The high levels of liposome 
uptake measured in smaller tumors may be 
explained by their higher vascular volumes 
compared to larger tumors.  
The diagnostic safety of 64Cu-liposomes as 
PET tracers was evaluated, and resulted in a total 
effective dose of less than 3.3·10-2 mSv/MBq for 
both 5 mol% and 10 mol% PEG liposomes, an 
acceptable radiation dose in clinical PET imaging 
according to ICRP guidelines [30]. The combination 
of PET scanners and computed tomographic (CT) 
scanners in clinical use provides co-registered 
images of anatomic and functional information as 
well as CT-based attenuation correction in a single 
study. In PET/CT scanning procedures, the effective 
dose is a combination of the dose from the PET and 
the dose from the CT. Therefore in addition to the 
radiation dose from the decaying 64Cu radionuclide, 
the dose from a whole-body CT scanning should be 
added to the total effective dose, and is normally 
estimated to be less than 10 mSv [31,32].  
A total effective dose less than 20 mSv per 
patient (both CT and PET) therefore predicts that a 
start administration activity of 200 MBq of 64Cu-
liposomes should be acceptable in a clinical study. 
The organs receiving the highest doses were 
spleen, liver, stomach wall, lower large intestine 
wall, red marrow and lungs, and similar critical 
organs were identified from the dosimetric analysis 
of data from a clinical study [28] yielding 
comparable effective doses. While an evaluation of 
the absorbed radiation dose based on preclinical 
studies provides a reasonable guideline, especially 
for identifying the most critical organs, caution must 
be exercised in interpreting such approximated 
absorbed radiation doses. Since variability in 
calculation approaches (particularly in 
implementation of the remainder-of-body) can 
result in erroneous estimated effective doses, direct 
comparisons between dosimetry studies should be 
considered carefully. Even though the 10 mol% 
PEG liposomes accumulated in a significant higher 
degree in the tumors, a less favorable T/M ratio was 
obtained (8.9 ± 0.9) compared to 5 mol% PEG 
liposomes (11.3 ± 1.3) 24 h after injection. From a 
diagnostic point of view a high T/M ratio together 
with a low total effective dose is favorable, 
rendering the 5 mol% PEG liposomes most suitable 
from a diagnostic and safety point of view.  
For the development of radiotherapeutic 
agents knowledge of absorbed radiation doses to 
various critical organs is crucial for a safe 
evaluation and understanding of the dose-response 
relationship of a potential radiotherapeutic agent. 
For 177Lu-liposomes to act as radiotherapeutic 
agents it is essential that they are highly stable in 
vivo and carry sufficient amounts of 177Lu 
radionuclides into the tumor tissue for an effective 
treatment. One challenge with internal radiation 
therapy is to deliver the highest possible dose to the 
tumor while sparing normal organs from damage. 
Furthermore, to achieve an effective treatment, a 
T/M ratio of at least 3-5 should be reached [33]. We 
have found that 177Lu3+ can be loaded into 
PEGylated liposomes as efficiently as 64Cu2+ 
(>95%) similar to a study reporting 111In/177Lu 
remote loading (>90%) in PEGylated liposomes 
using oxine [34]. While the 177Lu-liposomes in this 
study showed essentially no leakage when incubated 
in serum, a significantly lower retention of 
radionuclides (83%) was observed in previous study 
[34]. This observation may be explained by the 
higher binding affinity of 177Lu-DOTA compared to 
177Lu-DTPA [35,36].  
We foresee that selection of patients suited 
for 177Lu therapy would require a pretreatment 
evaluation for which 64Cu-liposome PET imaging is 
ideal. In addition, we have found that it is possible 
to load 64Cu and 177Lu simultaneously into the 
PEGylated liposomes (data not shown), thus 
providing a theranostic potential agent. This double-
loading 64Cu/177Lu approach could give a 
simultaneous visualization by PET of 177Lu-
liposome therapy (64Cu/177Lu-liposomes). Whether 
this PET based imaging approach is superior to 
SPECT imaging based on pure 177Lu-liposomes has 
yet to be proven, but it should provide superior 
diagnostic sensitivity [37] and does allow for 
quantification of lesion uptake by SUV. 
The high absorbed doses to the tumors 
estimated from the dosimetric analysis (114 
mGy/MBq and 11.5 mGy/MBq for 2-g and 20-g 
tumors respectively) suggested that an i.v. 
administration of 177Lu-liposomes could lead to an 
adequate delivery of therapeutic internal radiation to 
solids tumors. A significantly lower absorbed dose 
in tumors (5.74·10-2 mGy/MBq for a 20-g tumor) 
was obtained in a previous study [34], whereas 
comparable absorbed doses (9.7 mGy/MBq) was 
obtained from administration of 177Lu-DOTA-
TATE in patients with metastatic NE tumors [37]. 
The therapeutic potential of 177Lu-liposomes needs 
to be evaluated further in a tumor-bearing mouse 
model. One approach to improve the therapeutic 
performance of 177Lu-liposomes could be to utilize 
liposomes that target specific receptors within the 
tumor tissue. The liposomes described here can be 
labeled with ligands on the surface for target-
specific accumulation. A longer tumor residence 
time together with a shorter blood and liver 
residence time could possibly improve the dose-
response relationship between myelotoxicity and 
second organ toxicity given a safer internal 
radiotherapeutic treatment.  
 
Conclusion 
The aim of the study was to investigate the optimal 
level of PEGylation in liposomes and how this 
influences the biodistribution and tumor 
accumulation. A description of the organ and tumor 
kinetics of PEGylated liposomes was conducted to 
perform dosimetric calculations on diagnostic (64Cu) 
and therapeutic (177Lu) liposomes. The 10 mol% 
PEG liposomes showed significantly higher tumor 
accumulation compared to 5 mol% PEG liposomes. 
A larger accumulation of liposomes per tumor 
weight was observed for small tumors when 
compared to large tumors. The evaluation of the 
64Cu-liposomes as diagnostic tracers was successful 
with clear visualization of the tumors and an 
acceptable estimated total effective dose to patients 
of less than 3.3·10-2 mSv/MBq. Furthermore the 
dosimetry results predicted a starting administration 
activity of 200 MBq of 64Cu-liposomes should be 
acceptable in a clinical study. Thus, the overall 
preclinical profile of 64Cu-liposomes strongly 
indicates that this new PET radiotracer is a very 
promising candidate in diagnostic cancer imaging in 
humans. Work is in progress to validate the utility 
of 64Cu-liposomes in a clinical research programme. 
The 64Cu-liposomes have high potential for 
detection of a variety of malignancies and could be 
a significant addition to the currently available 
arsenal for cancer imaging. The remote loading of 
177Lu3+ into PEGylated liposomes was as efficient as 
the 64Cu2+ remote loading (>95%), and the 177Lu-
liposomes have the potential of carrying sufficient 
amount of 177Lu radionuclides into the tumor tissue 
for an effective radionuclide treatment. A high-
absorbed tumor dose (114 mGy/MBq) was 
estimated of the potential radiotherapeutic 177Lu-
liposomes. These preliminary dosimetric studies 
justify further therapeutic and dosimetry evaluation 
of 177Lu-liposomes localized radiotherapy in man. 
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 Appendix A: Tables of Absorbed Radiation Doses 
 
 
 
 
Table 3. Absorbed Radiation Doses of 64Cu-liposomes  
Target organ 10 mol% liposomes (mSv/MBq) 5 mol% liposomes (mSv/MBq) 
Adrenals 7.85 x 10-5 7.80 x 10-5 (8.31 x 10-5) 
Brain 5.99 x 10-5 6.06 x 10-5 (5.59 x 10-5) 
Breasts 1.20 x 10-3 1.21 x 10-3 (1.17 x 10-3) 
Gallbladder wall 0 0 (0) 
LLI wall 3.41 x 10-3 3.45 x 10-3 (3.21 x 10-3) 
Small intestine 7.37 x 10-5 7.43 x 10-5 (7.12 x 10-5) 
Stomach wall  3.59 x 10-3 3.60 x 10-3 (3.64 x 10-3) 
ULI wall 7.37 x 10-5 7.40 x 10-5 (7.19 x 10-5) 
Heart wall 0 0 (0) 
Kidneys 1.62 x 10-4 1.61 x 10-4 (2.34 x 10-4) 
Liver 3.86 x 10-3 3.39 x 10-3 (6.21 x 10-3) 
Lungs 3.30 x 10-3 3.29 x 10-3 (1.05 x 10-2) 
Muscle 6.52 x 10-5 6.56 x 10-5 (6.29 x 10-5) 
Pancreas 8.32 x 10-5 8.28 x 10-5 (8.89 x 10-5) 
Red marrow 2.73 x 10-3 2.74 x 10-3 (2.67 x 10-3) 
Osteogenic cells 5.30 x 10-4 5.36 x 10-4 (5.01 x 10-4) 
Skin 2.27 x 10-4 2.29 x 10-4 (2.16 x 10-4) 
Spleen 4.63 x 10-3 4.63 x 10-3 (9.04 x 10-3) 
Testes 0 0 (0) 
Thymus 6.99 x 10-5 6.95 x 10-5 (6.52 x 10-5) 
Thyroid 1.31 x 10-3 1.32 x 10-3 (1.24 x 10-3) 
Urinary bladder wall 1.41 x 10-3 1.42 x 10-3 (1.32 x 10-3) 
EDT 3.28 x 10-2 3.25 x 10-2 (4.60 x 10-2) 
LLI wall = lower large intestine wall; ULI = upper large intestine wall; EDT = total effective dose 
( ): residence times calculated based on human liposomal (5.3 mol% DSPE-PEG2000) biodistribution data from a clinical 
study and is an average of 17 patients [28]. 
  
 Table 4: Absorbed Radiation Doses of 177Lu-liposomes calculated from the 64Cu-liposome distribution  
  Target organ 10 mol% liposomes (mSv/MBq) 5 mol% liposomes (mSv/MBq) 
Adrenals 6.82 x 10-4 6.83 x 10-4 (6.53 x 10-4) 
Brain 6.53 x 10-4 6.55 x 10-4 (5.99 x 10-4) 
Breasts 1.28 x 10-2 1.29 x 10-2 (1.19 x 10-4) 
Gallbladder wall 0 0 (0) 
LLI wall 3.26 x 10-2 3.28 x 10-2 (3.00 x 10-2) 
Small intestine 6.83 x 10-4 6.85 x 10-4 (6.33 x 10-4) 
Stomach wall  3.25 x 10-2 3.25 x 10-2 (3.07 x 10-2) 
ULI wall 6.81 x 10-4 6.83 x 10-4 (6.33 x 10-4) 
Heart wall 0 0 (0) 
Kidneys 6.37 x 10-4 6.37 x 10-4 (1.59 x 10-3) 
Liver 2.14 x 10-2 1.86 x 10-2 (5.11 x 10-2) 
Lungs 3.19 x 10-2 3.20 x 10-2 (6.99 x 10-2) 
Muscle 6.59 x 10-4 6.61 x 10-4 (6.09 x 10-4) 
Pancreas 6.91 x 10-4 6.92 x 10-4 (6.71 x 10-4) 
Red marrow 2.44 x 10-2 2.44 x 10-2 (2.26 x 10-2) 
Osteogenic cells 8.21 x 10-3 8.24 x 10-3 (7.56 x 10-3) 
Skin 2.55 x 10-3 2.56 x 10-4 (2.35 x 10-3) 
Spleen 2.54 x 10-2 2.45 x 10-2 (9.99 x 10-2) 
Testes 0 0 (0) 
Thymus 6.64 x 10-4 6.66 x 10-4 (6.15 x 10-4) 
Thyroid 1.33 x 10-2 1.34 x 10-2 (1.22 x 10-2) 
Urinary bladder wall 1.35 x 10-2 1.36 x 10-2 (1.24 x 10-2) 
EDT 2.79 x 10-1 2.76 x 10-1 (4.08 x 10-1) 
Tumor (mGy/MBq) 114*/11.5** 96.9*/9.8** (NA) 
LLI wall = lower large intestine wall; ULI = upper large intestine wall; EDT = Total effective dose 
*Absorbed dose for a 2-g tumor 
**Absorbed dose for a 20-g tumor 
NA = not available 
( ): residence times calculated based on human liposomal (5.3 mol% DSPE-PEG2000) biodistribution data from a clinical 
study and is an average of 17 patients [28]. 
 
  
Appendix B: Equations 1-6 
 
The percentage of injected dose in blood (%IDblood) 
was calculated using: 
 %𝐼𝐷!"##$ = !!∙!.!%∙!!                          (1) 
 
where 𝐴!  is the decay corrected blood activity 
concentration at time t. The animal’s blood volume 
was calculated as 7.5% of the animal’s body weight, 𝑚. 𝐷 is the injected activity.  
 
 
The percentage of injected dose in blood (%IDblood) 
between 1 h and 48 h was fitted to the mono-
exponential equation: 
 %𝐼𝐷!"##$(𝑡) = 𝐵 ∙ 𝑒!!"                  (2) 
 
 
where 𝛽 is first-order disposition rate constant or 
the elimination rate constant, and 𝐵 represents the 
fraction of the injected dose, which is cleared from 
the blood at the disposition rate 𝛽. The fraction of 
the dose, which is cleared initially, can be estimated 
by 100% - 𝐵. The terminal half-life 𝑇½!  of the 
liposomes was determined using: 
  𝑇½! = !"#β                    (3) 
 
The data available did not permit accurate 
estimation of an initial half-life 𝑇½! . 
 
Accumulation in tumor and organs: Liposomal 
concentrations within each source organ as a 
function of time were determined from a ROI 
placed over the entire volume of the organ. The 
liposomal accumulation in the different organs was 
expressed as percentage of injected dose per gram 
(%ID/g) by using:  
 %𝐼𝐷/𝑔 = !!∙!                                (4) 
 
where  𝐴  is the decay corrected activity 
concentration in the tumor and normal organs, 
and  𝜌 is the organ density and is assumed to be 1 
g/cm3 for all organs and tumors. 
 
The liposomal accumulation in the tumor was 
further parameterized by the standardized uptake 
value (SUV) and the tumor-to-muscle (T/M) ratio. 
The SUV values were calculated using: 
  𝑆𝑈𝑉 = !∙!!∙!                      (5) 
 
where 𝑚  is the animal body weight and 𝐴 is the 
decay corrected activity concentration in the tumor. 
The PET data was not corrected for attenuation, 
which would give 5-15% higher 64Cu concentrations 
than the values provided in this study, depending on 
the tissue in focus.  
 
For the 64Cu-liposome dosimetry study, activity 
concentration data, which were not corrected for 
64Cu radioactive decay 𝐴 , were used to construct 
activity concentration-time curves for each source 
organ. For dose calculations the program 
OLINDA/EXM [38] was used. The residence times 
(𝑇!) from each source organs was used as input, and 
was calculated as: 
  𝑇! = !!"#$%! ∙ 𝐴 𝑑𝑡∞!                              (6) 
 
where 𝐴 is the activity concentration in the organ as 
function of time and 𝑉!"#$% is the volume of the 
source organ. Integration was done using the 
trapezoidal method to obtain the area up to the last 
measured activity concentration (𝐴∗). An estimate 
of the long-term tail of the activity concentration-
time curves for the different organs was made by 
fitting an exponential function (Â ~𝐴 ∙ 𝑒!!") to the 
two last measured points. The area beyond 𝐴∗ was 
then estimated by 𝐴∗/𝛽 . Since steady-state 
condition for the liposomal concentration within the 
measured tumor tissue was observed after 24 h (data 
not shown), the long-term tail of the activity 
concentration-time curves was assumed to be 
governed only by the radionuclide decay. The area 
beyond 𝐴∗ was thus estimated by 𝐴∗ ∙ !½!"!, where 𝑇½ 
is the half-life of the radionuclide. 
 
In the OLINDA/EXM program, activity not 
assigned to a specific organ must be assigned to the 
remainder-of-body category. In our calculation, this 
was estimated as the full injected dose activity 
received by the body excluding the source organ 
doses. A separate 𝑇! was assigned to the remainder-
of-body activity concentration-time curve.  
For the 177Lu-liposome dosimetry study, 
64Cu-liposomes were used as biological surrogates 
to study the biodistribution and estimate radiation 
dosimetry of 177Lu-liposomes. Thus, it was assumed 
that the 177Lu-liposomes virtually follow the same 
biodistribution and pharmacokinetics as the 64Cu-
liposomes due to the encapsulation of the 
radionuclides inside the liposomes prohibiting the 
exchange of the radionuclides with the biological 
environment. 64Cu-liposome activity data for each 
source organ corrected for 64Cu radioactive decay 
were multiplied by the physical decay of 177Lu 
( 𝑒!!"!/!½) to obtain estimates for the 177Lu-
liposome activity concentration in each source 
organ as a function of time. The 𝑇!  from each 
source organ was calculated via equation S6. 
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